- Lilly, Pfizer & The Economies of ED
- Is Pfizer's Viagra "Sagging" With The Economy?
- Merck And "Sex and the City" Strategy: Did It Work?
- Mystery Question-er On Merck & Schering-Plough's Vytorin
- Roche Offer For Genentech Sends Ripples Through Biotech
- Teva & Barr Get Super-Sized
- Pfizer--Is It Getting Wiser?
- Lilly's Sex Survey: Will It Have Desired Effect On Cialis?
- Genentech Regenerates Avastin
- Bobby Murcer Remembered
- Stop Trading!: A War on Wall Street
- Pisani: New ETF = Play on Mid-East Growth
- Existing Home Sales: A Look At Numbers That Weren't There
- Comicon: Not Just Funny Business
- See What People Are Saying About... Water Scarcity
- Microsoft's Ballmer Addresses Analysts
- Fast Money: Wall Street Got Drunk!
- Play the Coming Power-Grid Upgrade
- Microsoft's Johnson: What His Leaving Means For Company
- Gassing Up With Garbage
- UBS Target of Fraud Suit from NY Attorney General
- SEC Plans to Broaden Curbs on Short Sales: Cox
- 30-Year Bond Gains Full Point as Stocks Weaken
- FCC Agrees to Approve Sirius Pruchase of XM: Report
- Union Pacific Profit Rises, Beats Estimates
- Bristol Profit Beats Forecasts, Helped by Plavix
- Jobless Benefit Claims Rise above 400,000
- 3M Profit Up 3%, Tops Estimates

![]() |
CNBC.com |
The Securities and Exchange Commission is settling with Biovail [BVF
Loading...
()
] for a $10 million penalty. But the SEC is pursuing charges against Biovail founder and former CEO Eugene Melnyk, the former CFO and the current CFO and controller, both of whom the company says have been reassigned. You can read the SEC press release and the entire 55-page complaint here.
In an interview with me this afternoon, the Director of the SEC's New York Regional Office, Mark Schonfeld, wouldn't say if the four men had been offered a deal. But Melnyk issued a statement earlier today saying he will vigorously fight the charges which he calls, "absolutely false." He's a Canadian citizen who lives in Barbados.
Many of the charges stem from a truck accident in the fall of 2003. Biovail was shipping its anti-depressant Wellbutrin XL to its marketing partner GlaxoSmithKline [GSK
Loading...
()
] when the truck crashed in Illinois. Soonafter, the company put out a press release saying the wreck would demolish its earnings for that quarter. But at least one analyst didn't buy it.
So, David Maris, who worked at Bank of America at the time, and his team started to do some digging. They called the state trooper handling the crash investigation, got a copy of the accident report, talked to someone at the impound lot where the truck was towed. They also talked to the towing company, and to a local TV reporter or cameraperson who'd shot the scene and watched the report on the TV station's web site. His conclusion: that the truck was nearly empty. He told clients to sell BVF. Biovail then froze out Maris on company conference calls and it later sued him. They settled for a reported $2 million to pay off Maris' lawyers.
I always thought that was just good reporting by Maris and his team. As far as equity analysis is concerned, I guess your opinion of Team Maris' work would depend on which side of the BVF trade you were on.
The company has accused hedge funds of conspiring to drive down its stock price. The SEC's Schonfeld wouldn't comment on those allegations and he said he couldn't/wouldn't say if a criminal investigation has been or will be launched into the current and former execs. But when I asked him if not for Maris' work, would that part of the case have ever come to light, Schonfeld replied, "Part of the credit does go to people who were asking a lot of questions and were rightfully skeptical when the company was making representations that just didn't quite make sense."
Maris left B of A. He now works for a hedge fund where today, I imagine, he's feeling vindicated.
Questions? Comments?




